Day: March 27, 2020

Lundin Petroleum AB (Lundin Petroleum) announces that the first quarterly instalment of the proposed dividend of USD 0.25 per share will amount to SEK 2.49 per share, with a total amount of MSEK 707, corresponding to approximately MUSD 71. The proposed dividend, including the first quarterly instalment, remains subject to approval by the 2020 Annual General Meeting (AGM) that will be held on 31 March 2020.Information about the first quarterly instalment of the proposed dividend:The Board of Directors has proposed to the 2020 AGM a revised dividend proposal for 2019 of USD 1.00 per share, corresponding to MUSD 284 (rounded off), to be paid in quarterly instalments of USD 0.25 per share, corresponding to MUSD 71 (rounded off).According to the proposal, before payment, each quarterly dividend of USD 0.25 per share shall be converted into...

Lundin Petroleum AB (Lundin Petroleum eller bolaget) meddelar att den första kvartalsvisa utbetalningen av den föreslagna utdelningen om 0,25 USD per aktie kommer att uppgå till 2,49 SEK per aktie, med ett totalt utdelningsbelopp om 707 miljoner SEK, motsvarande cirka 71 miljoner USD. Den föreslagna utdelningen, inklusive den första kvartalsvisa utbetalningen, är fortsatt föremål för godkännande av 2020 års årsstämma som kommer att hållas den 31 mars 2020.Information om den första kvartalsvisa utbetalningen av den föreslagna utdelningen:Styrelsen har till 2020 års årsstämma föreslagit en reviderad utdelning för 2019 om 1,00 USD per aktie, motsvarande 284 miljoner USD (avrundat), att betalas ut genom kvartalsvisa delbetalningar om 0,25 USD per aktie, motsvarande 71 miljoner USD (avrundat).I enlighet med förslaget ska varje kvartalsvisa...

PHOENIX, March 27, 2020 (GLOBE NEWSWIRE) — Mobivity Holdings Corp. (MFON), creators of the award-winning customer personalization platform, Recurrency, today announced that the Company will release results for the fourth quarter and year ended December 31, 2019 on Monday, March 30, 2020 after the market close and has scheduled a conference call for the same day at 4:30 P.M. Eastern Time (ET).Conference Call Information:Date: Monday, March 30, 2020Time: 4:30 P.M. Eastern Time (ET)Dial in Number for U.S. Callers: 1 (877) 705-6003Dial in Number for International Callers: 1 (201) 493-6725Please Reference Conference ID: 13700252The call will also be accompanied live by webcast over the Internet and accessible here.Participating on the call will be Mobivity Holding Corp.’s Chairman and Chief Executive Officer, Dennis Becker, and Chief...

EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is based on Phase III PREVENT data1 If approved, Cosentyx would become the first fully-human IL-17A inhibitor indicated for patients in Europe with nr-axSpA There are approximately 1.7 million patients with nr-axSpA in the top five EU countries and US, which forms part of the axial spondyloarthritis (axSpA) disease spectrum2 Cosentyx is backed by five years of clinical data supporting long-term safety and efficacy across ankylosing spondylitis (AS), psoriatic arthritis (PsA) and moderate-to-severe plaque psoriasis (PsO)3-6Basel, March 27, 2020 — Novartis, a leader in rheumatology and immuno-dermatology,  today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...

Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, has been recommended for European Commission (EC) conditional approval for patients with spinal muscular atrophy (SMA) and a clinical diagnosis of Type 1 or SMA patients with up to three copies of the SMN2 gene Zolgensma has demonstrated significant and clinically meaningful therapeutic benefit in presymptomatic and symptomatic SMA, including prolonged event-free survival and achievement of motor milestones unseen in natural history of the disease and to date, sustained for 5 years post-dosing In Europe, SMA is a significant burden to the healthcare system with cumulative estimated healthcare costs per child ranging between €2.5 to €4 million within the first 10 years alone1 To support the urgent need to treat SMA as early as possible, AveXis is offering an innovative...

YERINGTON, Nev., March 27, 2020 (GLOBE NEWSWIRE) — Nevada Copper Corp. (TSX: NCU) (“Nevada Copper” or the “Company’’) is pleased to announce the execution of definitive agreements in respect of the Company’s proposed substantial balance sheet strengthening package announced on March 18, 2020.The financing package provides improved flexibility for the Company’s balance sheet whilst ramping-up operations and in light of the substantial macro-economic uncertainty and depressed copper prices.Nevada Copper has in place COVID-19 response plans and currently its operations are continuing with limited disruption. However, there are no guarantees that in the future further work restrictions will not be required, or government mandated, as events continue to unfold relating to COVID-19.Matt Gili, Chief Executive Officer, commented: “The successful...

NEW YORK, March 27, 2020 (GLOBE NEWSWIRE) — Prospect Capital Corporation (the “Company”) today announced the results of its previously announced cash tender offer (the “Tender Offer”) to purchase any and all of the outstanding notes listed below. The Tender Offer was made pursuant to an Offer to Purchase dated March 20, 2020 (the “Offer to Purchase”), which set forth the terms and conditions of the Tender Offer.As of the previously announced expiration time of 5:00 p.m., New York City time, on March 26, 2020 (the “Expiration Time”), according to information provided by D.F. King & Co., Inc., the information and tender agent for the Tender Offer, a total of $654,600 aggregate principal amount of Notes (defined below) had been validly tendered and not validly withdrawn in the Tender Offer. This amount includes $0 tendered pursuant...